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CObjectives: Health-related quality of life (HRQoL) and quality-adjusted
life-years (QALYs) gained are basic elements in the cost-utility evalua-
tions of health care. Different HRQoL instruments produce different
scores for the same patient, and thus also a different number of QALYs.
We examined the effect of these factors on the number of QALYs
gained and the cost per QALY in the critical care setting. Methods: In
937 patients having been treated in the critical care setting in the Hel-
sinki University Central Hospital the HRQoL scores were measured by
the EQ-5D and 15D 6 and 12months after start of treatment, andQALYs
were calculated using four different sets of assumptions regarding re-
covery from disease. Results: Themean number of QALYs gained dur-
ing the first year after treatment ranged from 0.178  0.206 to 0.550  O
r Hea
al So
doi:10.1016/j.jval.2011.05.047.508 and the consequent cost per QALY from €38,405 to €118,668 de-
ending on HRQoL instrument and assumptions used in the calcula-
ions regarding recovery from disease. Conclusions: The HRQoL in-
trument and the assumptions employed regarding recovery from
isease have a great influence on the results of cost-utility analyses
nd should, therefore, be explicitly described in studies reporting
ALYs. Furthermore, a common consensus on which calculation
ethod should be used within critical care would be urgently needed.
eywords: HRQoL, QALY, calculation method, EQ-5D, 15D.
opyright © 2011, International Society for Pharmacoeconomics and
utcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Recently, attention has been paid to differences in themethodology
of estimating quality-adjusted life years (QALYs) for patients under-
going an intervention, andhow these differences affect the results of
cost-utility analyses [1,2]. The calculation of QALYs is based on qual-
ity of life scores (utilities) that are obtained from patients filling in a
generic utility-generatinghealth-relatedquality of life (HRQoL) ques-
tionnaire at baseline, and at one or several time points during the
study period (e.g., at 6 and 12months).Within critical care, however,
it is not usually possible for a patient to fill in questionnaires and,
therefore, assumptions about the baseline HRQoL have to be made.
One commonlyusedapproach is to assume thatwithout treatment a
patient would die and use a baseline HRQoL score of zero [3–5]. An-
other possibility is to ask health care professionals to estimate the
baseline HRQoL based on patient records [6].
Another problem in the calculation of QALYs is the fact that dif-
erent instruments produce different HRQoL scores for the same pa-
ient [7–9]. Furthermore, even when using the same instrument, dif-
erences in the number of QALYs gainedmay arise from at least two
ources. The first of them is related to assumptions concerning the
volution of HRQoL betweenmeasurement points because continu-
us measurement is usually impossible. Three assumptions have
een presented: 1) HRQoL changes linearly between measurements
* Address correspondence to: Tarja Vainiola, National Institute fo
E-mail: tvainiol@mappi.helsinki.fi.
1098-3015/$36.00 – see front matter Copyright © 2011, Internation
Published by Elsevier Inc.(most frequently used in the literature); 2) HRQoL remains constant
fromonemeasurement to the next and then changes overnight; and
3) HRQoL changes at the midpoint between measurements [10]. In
the critical care setting the latter two alternatives are problematic
when the calculationofQALYs is basedon theassumption thatwith-
out treatment patients would die. Consequently, some critical care
QALY calculations have used a fourth alternative, namely the as-
sumption that the change in HRQoL for better or worse takes place
immediately [11]. The second source for possible variance in the
number of QALYs is related to how the commonly used area-under-
the-curve (AUC) method is applied because it makes a difference if
the whole AUC is calculated or only the area above/below the base-
line utility value [1,2].
Because QALYs, and the cost per QALY, play an increasingly
important role in the allocation of health care resources, we set
out to study, and using real life data, what the magnitude of the
above mentioned factors is on the results of cost-utility analyses
in the critical care setting.
Methods
The data were collected prospectively in the Helsinki University
Hospital between January 1, 2003, and December 31, 2004. The
study was approved by the local Ethics Committee. Two HRQoL
lth and Welfare, P.O. Box 30, FI-00271 Helsinki, Finland.
ciety for Pharmacoeconomics and Outcomes Research (ISPOR).
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address 6 and 12 months after start of intensive care unit (ICU) or
high-dependency unit (HDU) treatment together with a one-page
letter, informed consent form, and a prepaid envelope for return-
ing the signed consent form and the questionnaires. In case of
nonresponse one reminder was sent. The data used for analysis
consist of patients who returned the completely filled HRQoL
questionnaires both at 6 and 12 months, or had died during that
period (because their HRQoL score at 6 or 12 months was known;
that is, 0) and on whom diagnostic information was available. For
those who died before the end of the follow-up, QALYs were cal-
culated using their observed survival time. Furthermore, only pa-
tients receiving care on an emergency basis (i.e., those whose ad-
mission to both the hospital and ICU or HDU occurred on the same
day) were included and patients undergoing routine follow-up in
an ICU after an elective procedure were excluded. One year direct
secondary care costs (in- and outpatient hospital treatment) were
obtained from the Ecomed clinical patient administration system
(Datawell Ltd., Finland), where all costs of treatment of individual
patients in the hospital are routinely stored.Fig. 1 – Quality-adjusted life year calculation mThe HRQoL Instruments
The EQ-5D consists of five dimensions with one item on each:
mobility, self-care, usual activities, pain or discomfort, and anxi-
ety or depression. Each dimension is divided into three levels: no
problems, some problems, and severe problems. For the calcula-
tion of EQ-5D scores we used the UK time-trade-off tariff, which is
the most commonly used valuation system for the EQ-5D interna-
tionally. According to it the HRQoL scores range from 0.59 to 1,
here one means full health and zero stands for death. No health
tate can obtain a score between 0.88 and 0.99, and negative scores
ndicate health states worse than death (WTD) [12].
The 15D consists of 15 dimensions with one item on each:
reathing, mental function, speech, vision, mobility, usual ac-
ivity, vitality, hearing, eating, elimination, sleeping, distress,
iscomfort and symptoms, depression, and sexual activity.
ach dimension is divided into five levels from no problems to
xtreme problems. The HRQoL scores of the 15D range from 0 to
, with one being equivalent to full health and zero equivalent
o death [13].ethods based on Assumption Sets 1 to 4.
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The number of QALYs produced by ICU or HDU treatment within
the year following the admission to ICU or HDU care was calcu-
lated on the basis of four different sets of assumptions and using
two different baseline HRQoL scores (either zero assuming that
without treatment patients would die, or a HRQoL score assessed
by health care professionals based on patient records).
Assumption Set 1 (AS1). Without treatment patients would die;
that is, their HRQoL score would be zero and thus no QALYs would
be gained. With treatment the HRQoL changes immediately to the
level observed at the first follow-up point (in our case at 6months)
after which it changes linearly to the HRQoL observed at the sec-
ond follow-up point (in our case at 12 months). This implies that
for those who die before the first follow-up, the QALY gain is zero.
Theoretically the maximum number of QALYs gained is one. The
AS1 panel of Figure 1 illustrates these assumptions and how the
QALYs gained by treatment (shaded area under the curve  area
a  area b  0.4  T1 [(0.8  0.4)/2]  T2  0.5) are estimated as
he whole AUC. T1 is time alive in years between admission and
he first follow-up and T2 is time alive in years between the first
nd second follow-up. With EQ-5D all these changes can also take
lace in the negative area (i.e., WTD) between -0.59 and 0 (this
pplies also to all other assumption sets).
Assumption Set 2 (AS2). The assumption that without treatment
he patientswould die immediately is the same as in AS1, but with
reatment the change inHRQoL frombaseline to the first follow-up
s assumed to take place linearly. Theoretically the maximum
umber of QALYs gained is 0.750. The AS2 panel of Figure 1 illus-
rates these assumptions and how the QALYs gained by treatment
shaded AUC area a area b (0.4/2) T1 [(0.4 0.8)/2] * T2
0.4) are estimated as the whole AUC.
Assumption Set 3 (AS3). Without treatment patients are not as-
sumed to die, but to stay at the baseline self-reported or proxy-
assessed HRQoL level for the whole follow-up period. With treat-
ment the HRQoL changes immediately to the level measured at 6
months after which it changes linearly to the HRQoL score ob-
served at 12 months. The maximum number of QALYs gained
depends on the baseline HRQoL score. The AS3 panel of Figure 1
illustrates these assumptions and how the QALYs gained by treat-
ment (shadedAUC area a area b 0.4T1 [(0.40.8)/2T2]
0.2  T3  0.3) are estimated as the area above/below the base-
line HRQoL score. T3 is the length of the follow-up in years
(T1T2).
Assumption Set 4 (AS4). The assumptions are otherwise the
same as in the AS3, but with treatment the change in HRQoL from
baseline to the first follow-up and between follow-ups is assumed
to take place linearly. The maximum number of QALYs gained
depends on the baseline HRQoL score. The AS4 panel of Figure 1
Table 1 – Mean proxy-assessed (by two health care profess
to the EQ-5D and the 15D based on information obtained f
Diagnostic group Mean EQ-5D score Mean 15D sco
Resuscitated patients 0.59 0.11
Neurological diseases 0.51 0.15
Respiratory organ diseases 0.41 0.25
Intoxication 0.42 0.21
Infectious diseases 0.46 0.24
Gastrointestinal diseases 0.38 0.39
Other diseases 0.25 0.41
Vascular diseases 0.34 0.53
Heart diseases 0.09 0.53
On average 0.39 0.29illustrates these assumptions and how the QALYs gained by treat-
ment (shaded AUC  area a  area b  [(0.20.4)/2]  T1  [(0.4 
0.8)/2]  T2 – 0.2  T3  0.25) are estimated as the area above/
below the baseline HRQoL score.
The Baseline HRQoL
For the AS3 and AS4 the HRQoL of patients at admission was as-
sessed retrospectively based on information obtained from pa-
tients’ medical and nursing records. All baseline assessments
were performed by two persons: a physician (TK or RPR) and a
registered nurse with a long history of ICU work (TV). The infor-
mation was mapped onto the 15D and EQ-5D questionnaires and
the corresponding scores were derived. The patients were classi-
fied into ten diagnostic groups according to the ICD10 and every
10th patient was selected from each diagnostic group for baseline
evaluation. The targetwas to evaluate 18 patients in each diagnos-
tic group but because all patient records could not be retrieved,
and 19 patients were excluded because they received routine fol-
low-up care after an elective procedure, the final number of pa-
tients evaluatedwas 112. The HRQoL proxy assessment was based
on the status of the patient at admission to the ICU or HDU. The
baseline HRQoL used for the analyses was the average of all as-
sessments in each diagnostic group (Table 1).
Statistical Methods
The results of QALY calculations are presented using descriptive
statistics (i.e., mean, standard deviation, range, and proportions).
Differences in the mean number of QALYs obtained with the two
HRQoL instruments were compared with paired samples t test,
and differences in medians and distributions with the Wilcoxon
Signed Ranks Test. Chi-square test was used to find out if the
distribution of proxy-assessed patients across diagnostic groups
deviates from that of all ICU patients across these groups. P 0.05
was considered statistically significant.
Results
There were 3600 patients treated at HCU or HDU during the study
period. Of them 1990 patients fulfilled the inclusion criteria. Be-
cause 451 patients died before the first follow-up there were 1539
patients alive at 6 months and of them 486 (31.6%) returned both
questionnaires. Between 6 and 12months another 17 patients died
and 469 patients returned the 12-month questionnaire. One-year
mortality was thus 23.5%. Thosewho had died before the 6-month
follow-up were included in the analyses (because their HRQoL
score could be set at zero) aswere also thosewho had returned the
ls) baseline health-related quality of life scores according
patient records.
No. of assessed
patients
Percentage of patients in proxy-assessed
baseline group/percentage of patients in
intensive care unit population
15 13.4/8.5
10 8.9/9.6
11 9.8/5.6
16 14.3/13.7
14 12.5/13.2
12 13/13.8
19 17.0/14.1
7 6.3/8.1
8 7.1/13.4iona
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low-up at 12 months. Altogether the study group consists thus of
937 patients, 47.1% of the basic population.
The respondents and nonrespondents differed statistically sig-
nificantly regarding length of stay at ICU or HDU (5.5 vs. 4.3 days;
P  0.001), costs of treatment (€21,103 vs. €18,129; P 0.006) and age
(61 vs. 54; P  0.001) indicating that respondents had a slightly
more severe disease than the nonrespondents. Sixty-two percent
of respondents were men and the mean length of hospital stay
was 14.0 days. Themeanutility score at 6months for patients alive
was 0.820 (CI 95% 0.808–0.832) for the 15D and 0.714 (CI 95% 0.690–
0.738) for the EQ-5D, respectively. At 12 months the mean scores
were 0.830 (CI 95% 0.818–0.842) and 0.727 (CI 95% 0.702–0.752),
respectively. The distribution of proxy-assessed patients across
diagnostic groups did not deviate statistically significantly from
that of all ICU patients across these groups (P  0.151).
Themean number of QALYs gained calculated using the 15D or
the EQ-5D differed significantly in all assumption sets; both be-
tween instruments and within each instrument (P  0.001) (Table
2). With the AS1 and AS2 the 15D produced on average slightly
moreQALYs than the EQ-5D. By contrast, with theAS3 andAS4 the
EQ-5D produced on average two times more QALYs than the 15D.
With the AS3 and AS4 the 15D produced considerably more often
negative QALYs than the EQ-5D, but the latter produced negative
QALYs with all assumption sets. The variation in the number of
QALYs gained (in percentages of standard based onAS1 and EQ-5D
and set at 100) using different sets and HRQoL instruments, is
shown in Figure 2. During the 1-year follow-up the 15D and EQ-5D
produced one QALY with AS1 (which is the maximum number of
QALYs that can be gained when using HRQoL instruments with
scores ranging between zero and one) in 1.9% and 10.1% of cases,
respectively. The EQ-5D produced more than one QALY with AS3
and AS4 in 30.5% and 7.4% of cases, respectively. The maximum
Table 2 – The number of QALYs gained using the 15D and
and four different assumption sets for calculation of qualit
AS1 AS
15D EQ-5D 15D
Mean 0.42 0.37 0.31
SD 0.41 0.40 0.31
Median 0.19 0.08 0.39
Min 0 0.30 0
Max 1 1 0.75
Negative QALY (%) 0 1.4 0
Cost/QALY 50,412 57,713 67,271
Fig. 2 – The variation in the number of QALYs gained (as
percentage of standard based on assumption set (AS) 1
And EQ-5D and set at 100 using different sets and health-
related quality of life instruments (N = 937).number of QALYs within a year was 1.594 with the EQ-5D. For the
15D the maximum QALY gain was one QALY (Table 2).
Like the number of QALYs, also the cost per QALY gained var-
ied within a very wide range depending on the HRQoL instrument
and assumption set used. With the instrument constant, the as-
sumption set used resulted atmaximum over double difference in
the cost per QALY.With the assumption set fixed, the choice of the
instrument resulted at maximum in more than doubling of the
cost per QALY (Table 2).
Discussion
This study set out to explore the implications of using different
HRQoL instruments and assumption sets for assessing the num-
ber of QALYs gained within the year following admission to ICU or
HDU treatment. Both the HRQoL instrument and the assumption
set used had a significant effect on the total number of QALYs
gained. The calculation methods based on the estimated baseline
HRQoL (i.e., AS3 and AS4) produced clearly less QALYs with the
15D than the methods based on the assumption that without
treatment patients would die (i.e., AS1 and AS2). But with the
EQ-5D the situation was opposite, the calculation methods based
on the estimated baseline HRQoL (i.e., AS3 and AS4) produced
more QALYs than the methods based on the assumption that
without treatment patients would die (i.e., AS1 and AS2).
The crucial assumption of the AS1 and AS2 is that without ICU
or HDU treatment all patients would have died immediately or
very quickly. Thus all observed survival and HRQoL of patients is
attributed to ICU or HDU treatment. This assumption is certainly
valid inmost ICU and inmanyHDUpatients, but not always. Thus,
when applying the calculation methods AS1 and AS2, the QALYs
gained by those, who without ICU or HDU treatment would have
stayed alive for different durations of time at different levels of
HRQoL, are omitted. Consequently, AS1 and AS2 overestimate the
incremental QALYs gained by ICU or HDU treatment. On the other
hand, these approaches omit theQALYs gained by those,whowith
ICU or HDU treatment stayed alive at different levels of HRQoL for
some time, but not until the first follow-up point, and may thus
also underestimate the QALYs gained by ICU or HDU treatment.
In AS1 and AS2 the assumption that all patients have at baseline
the HRQoL score of zero (dead) conceals an important difference be-
tween instruments that produce negative (worse than death) values
for health states (like the EQ-5D) and those, that do not (like the 15D).
In the follow-upmeasurements with the EQ-5D the patients can ob-
tain negative HRQoL values and thus gain negative QALYs as can be
seen fromTable 2. This raises a philosophical and ethical problemof
whether dying immediately produces in factmoreQALYs (zero) than
living in a state worse than death for some time—purelymathemat-
ically zero is more than any negative number.
AS3 and AS4 require that at admission to an ICU or HDU pa-
Q-5D for the assessment of health-related quality of life
justed life years (QALYs) (N = 937).
AS3 AS4
Q-5D 15D EQ-5D 15D EQ-5D
0.27 0.23 0.55 0.18 0.41
0.30 0.28 0.54 0.21 0.40
0.07 0.13 0.42 0.10 0.32
0.22 0.21 0.07 0.11 0.05
0.75 0.88 1.59 0.66 1.20
1.4 16.5 2.0 16.5 2.0
6,811 90,657 38,405 118,668 51,269the E
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1134 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 1 1 3 0 – 1 1 3 4cases it may be impossible to derive it based on patient self-report
and it has to be assessed by a proxy. It can, of course, be ques-
tioned whether the HRQoL estimates by proxies are in agreement
with those of the patients themselves. There is evidence from the
intensive care setting to suggest though that the estimates by
close proxies [14,15] and even by professionals are in relatively
ood agreement with those of patients [16]. Although the proxy
ssessedHRQoL could be acceptable, our target is not to generalize
he baseline HRQoL assessed and used in this study to all studies
n the critical care setting. The baseline scores are theoretical es-
imates derived for this study from empiric data to enable the
ALY calculation by the AS3 and AS4.
The 15D score is by definition always positive, whereas the
Q-5D score can in many cases be also negative (i.e., WTD). With
S3 and AS4 the 15D (and the EQ-5D with a positive score at base-
ine) can produce negative QALYs if a patient dies before 6months
r if the score at 6months is lower than at baseline. In that case the
UC is smaller than the white area under the shaded area for AS3
nd AS4 in Figure 1. Thus dying brings a loss in QALYs as can be
een in a number of cases in Table 2. In addition, the EQ-5D can
roduce negative QALYs if the baseline HRQoL score is negative
nd the majority of the area above/under the curve is on the neg-
tive side. If a patient is at baseline in the worst EQ-5D score of
0.59, AS3 can produce a maximum of 1.59 QALYs in 1 year, if the
RQoL score at 6 months is one and remains at that level until 12
onths.
In trials dealing with elective care AS4 is the most frequently
sed approach for the calculation of QALYs in the literature [1].
hen applying AS3 and AS4 in the critical care setting; however,
he assumption that without ICU or HDU treatment all patients
ould live the whole year at the baseline level of HRQoL does not
old in practice. With treatments available outside ICUs or HDUs
any patients would have died immediately and some would
ave lived for unknown durations at unknown levels of HRQoL.
hus those assumptions may result in an overestimate of QALYs
o be experienced without ICU or HDU treatment.
In critical care, the rule of rescue; that is, the duty to safe en-
angered life where possible benefit can be seen, applies and,
herefore, we do not know what would happen to the patients in
erms of length and quality of life by just “conventional” treat-
ent. This is also difficult to establish, as it would, in most cases,
e unethical to organise a trial, where patients would be ran-
omised to obtain ICU/HDU or conventional treatment. Conse-
uently, studies evaluating the effectiveness of critical care must
lways be based on assumptions. To be able to compare the cost-
ffectiveness of treatments across a variety of medical specialties,
imilar assumptions should be used irrespective of if care is pro-
ided on an emergency or elective basis. Because it is difficult to
ay which assumption set is the most realistic one in the critical
are setting, there is a clear need for sensitivity analyses using
ifferent assumption sets when reporting results of studies.
Because both the choice of the HRQoL instrument and the as-umption set regarding progression of disease have a significantffect on the total number of QALYs gained, it is evident that also
he cost/QALY varies within a wide range. Our results should be
een as a theoretical example of how different instruments and
ssumptions play a major role in the calculation of QALYs and
tress the fact that when reporting results of cost-utility studies in
he critical care setting, special attention should be paid to de-
cribing how the QALYs have been calculated. Otherwise the com-
arison of the results of different studies is futile.
Source of financial support: Funding for this project was pro-
ided by the Helsinki University Central Hospital and the Yrjö
ahnsson Foundation. Harri Sintonen is the developer of the 15D
nstrument and one of the developers of the EQ-5D instrument.
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